한글목차

피부 B세포 림프종(CBCL) 치료의 동향과 예측

세계의 피부 B세포 림프종(CBCL) 치료 시장은 2024-2030년 CAGR 2.3%로 성장할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 첨단 표적 치료의 채택 확대, 임상 에비던스의 실증 이용 증가, 또한 피부 B세포 림프종(CBCL)을 치료하기 위한 신제품 개발을 위한 연구개발 투자의 증가입니다. 세계의 피부 B세포 림프종(CBCL) 치료 시장의 미래는 병원·전문 클리닉 시장에서의 비즈니스 기회에 의해 유망시되고 있습니다.

피부 B세포 림프종(CBCL) 치료 시장 인사이트

Lucintel의 예측에서 화학요법은 진행 사례에 대한 유효성과 다른 병기에 대한 적응성으로 인해 예측 기간 중 가장 높은 성장이 전망됩니다.

북미는 예측 기간 중 가장 높은 성장이 전망됩니다.

본 리포트는 아래 11개의 주요 질문에 답변하고 있습니다. :

• Q.1.시장 부문 중 가장 유망하고 고성장인 기회는 무엇인가?
• Q.2.어느 부문이 보다 빠른 페이스로 성장하는가, 또 이유는?
• Q.3.향후 성장이 가속할 것으로 생각되는 지역과 이유는?
• Q.4.시장 역학에 영향을 미치는 주요 요인은 무엇인가? 시장에서 주요 과제와 비즈니스 리스크는?
• Q.5.이 시장에서 비즈니스 리스크와 경쟁의 위협은?
• Q.6.이 시장에서 새로운 동향과 이유는?
• Q.7.시장에서 고객의 수요 변화에는 어떤 것이 있는가?
• Q.8.이 시장에서 새로운 개발과 개발을 선도하고 있는 기업은?
• Q.9.이 시장의 주요 기업은? 주요 기업은 사업 성장을 위해 어떤 전략적 구상을 진행시키고 있는가?
• Q.10.이 시장에서 경쟁 제품은 무엇이며, 재료 및 제품의 대체에 의한 시장 점유율 하락의 위협은 어느 정도인가?
• Q.11.과거 5년간 어떤 M&A가 시행되고, 업계에 어떤 영향을 미쳤는가?

목차

제1장 주요 요약

제2장 세계의 피부 B세포 림프종(CBCL) 치료 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 2018-2030년의 시장 동향과 예측 분석

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 피부 B세포 림프종(CBCL) 치료 시장 동향(2018-2023년)과 예측(2024-2030년)
• 유형별 세계의 피부 B세포 림프종(CBCL) 치료 시장
  • 방사선요법
  • 화학요법
  • 모노클로널 항체
  • 기타
• 최종 용도별 세계의 피부 B세포 림프종(CBCL) 치료 시장
  • 병원
  • 전문 클리닉
  • 기타

제4장 2018-2030년의 지역별 시장 동향과 예측 분석

• 지역별 세계의 피부 B세포 림프종(CBCL) 치료 시장
• 북미의 피부 B세포 림프종(CBCL) 치료 시장
• 유럽의 피부 B세포 림프종(CBCL) 치료 시장
• 아시아태평양의 피부 B세포 림프종(CBCL) 치료 시장
• 기타 지역의 피부 B세포 림프종(CBCL) 치료 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영상의 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략적 분석

• 성장 기회 분석
  • 유형별 세계의 피부 B세포 림프종(CBCL) 치료 시장의 성장 기회
  • 최종 용도별 세계의 피부 B세포 림프종(CBCL) 치료 시장의 성장 기회
  • 지역별 세계의 피부 B세포 림프종(CBCL) 치료 시장의 성장 기회
• 세계의 피부 B세포 림프종(CBCL) 치료 시장의 새로운 동향
• 전략적 분석
  • 신제품의 개발
  • 세계의 피부 B세포 림프종(CBCL) 치료 시장의 능력 확대
  • 세계의 피부 B세포 림프종(CBCL) 치료 시장에서의 합병, 인수, 합병사업
  • 인증과 라이선싱

제7장 유력 기업의 기업 개요

• Kite Pharma
• Genentech
• Novartis
• Epizyme
• NanoString Technologies
• Amgen
• Johnson & Johnson Services

영문목차

Cutaneous Bcell Lymphoma Treatment Trends and Forecast

The future of the global cutaneous Bcell lymphoma treatment market looks promising with opportunities in the hospitals, and speciality clinics markets. The global cutaneous Bcell lymphoma treatment market is expected to grow with a CAGR of 2.3% from 2024 to 2030. The major drivers for this market are growing adoption of advanced and targeted therapies, increasing usage of clinical evidence demonstrating, as well as, rising investments in research and development to develop novel products to cure cutaneous Bcell lymphoma.

A more than 150-page report is developed to help in your business decisions.

Cutaneous Bcell Lymphoma Treatment by Segment

The study includes a forecast for the global cutaneous Bcell lymphoma treatment by type, end use, and region.

Cutaneous Bcell Lymphoma Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Radiation Therapy
• Chemotherapy
• Monoclonal Antibodies
• Others

Cutaneous Bcell Lymphoma Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Speciality Clinics
• Others

Cutaneous Bcell Lymphoma Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Cutaneous Bcell Lymphoma Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cutaneous Bcell lymphoma treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cutaneous Bcell lymphoma treatment companies profiled in this report include-

• Kite Pharma
• Genentech
• Novartis
• Epizyme
• Nanostring Technologies
• Amgen
• Johnson & Johnson Services

Cutaneous Bcell Lymphoma Treatment Market Insights

Lucintel forecasts that chemotherapy is expected to witness highest growth over the forecast period because of its effectiveness in advanced case and adaptability to different disease stages.

North America is expected to witness highest growth over the forecast period.

Features of the Global Cutaneous Bcell Lymphoma Treatment Market

Market Size Estimates: Cutaneous Bcell lymphoma treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cutaneous Bcell lymphoma treatment market size by type, end use, and region in terms of value ($B).

Regional Analysis: Cutaneous Bcell lymphoma treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, end use, and regions for the cutaneous Bcell lymphoma treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cutaneous Bcell lymphoma treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for cutaneous Bcell lymphoma treatment market?

Answer: The global cutaneous Bcell lymphoma treatment market is expected to grow with a CAGR of 2.3% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the cutaneous Bcell lymphoma treatment market?

Answer: The major drivers for this market are growing adoption of advanced and targeted therapies, increasing usage of clinical evidence demonstrating, as well as, rising investments in research and development to develop novel products to cure cutaneous Bcell lymphoma.

Q3. What are the major segments for cutaneous Bcell lymphoma treatment market?

Answer: The future of the global cutaneous Bcell lymphoma treatment market looks promising with opportunities in the hospitals, and speciality clinics markets.

Q4. Who are the key cutaneous Bcell lymphoma treatment market companies?

Answer: Some of the key cutaneous Bcell lymphoma treatment companies are as follows:

• Kite Pharma
• Genentech
• Novartis
• Epizyme
• Nanostring Technologies
• Amgen
• Johnson & Johnson Services

Q5. Which cutaneous Bcell lymphoma treatment market segment will be the largest in future?

Answer: Lucintel forecasts that chemotherapy is expected to witness highest growth over the forecast period because of its effectiveness in advanced case and adaptability to different disease stages.

Q6. In cutaneous Bcell lymphoma treatment market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the cutaneous Bcell lymphoma treatment market by type (radiation therapy, chemotherapy, monoclonal antibodies, and others), end use (hospitals, speciality clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cutaneous Bcell Lymphoma Treatment Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Cutaneous Bcell Lymphoma Treatment Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Cutaneous Bcell Lymphoma Treatment Market by Type
  • 3.3.1: Radiation Therapy
  • 3.3.2: Chemotherapy
  • 3.3.3: Monoclonal Antibodies
  • 3.3.4: Others
• 3.4: Global Cutaneous Bcell Lymphoma Treatment Market by End Use
  • 3.4.1: Hospitals
  • 3.4.2: Speciality Clinics
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Cutaneous Bcell Lymphoma Treatment Market by Region
• 4.2: North American Cutaneous Bcell Lymphoma Treatment Market
  • 4.2.2: North American Cutaneous Bcell Lymphoma Treatment Market by End Use: Hospitals, Speciality Clinics, and Others
• 4.3: European Cutaneous Bcell Lymphoma Treatment Market
  • 4.3.1: European Cutaneous Bcell Lymphoma Treatment Market by Type: Radiation Therapy, Chemotherapy, Monoclonal Antibodies, and Others
  • 4.3.2: European Cutaneous Bcell Lymphoma Treatment Market by End Use: Hospitals, Speciality Clinics, and Others
• 4.4: APAC Cutaneous Bcell Lymphoma Treatment Market
  • 4.4.1: APAC Cutaneous Bcell Lymphoma Treatment Market by Type: Radiation Therapy, Chemotherapy, Monoclonal Antibodies, and Others
  • 4.4.2: APAC Cutaneous Bcell Lymphoma Treatment Market by End Use: Hospitals, Speciality Clinics, and Others
• 4.5: ROW Cutaneous Bcell Lymphoma Treatment Market
  • 4.5.1: ROW Cutaneous Bcell Lymphoma Treatment Market by Type: Radiation Therapy, Chemotherapy, Monoclonal Antibodies, and Others
  • 4.5.2: ROW Cutaneous Bcell Lymphoma Treatment Market by End Use: Hospitals, Speciality Clinics, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Cutaneous Bcell Lymphoma Treatment Market by Type
  • 6.1.2: Growth Opportunities for the Global Cutaneous Bcell Lymphoma Treatment Market by End Use
  • 6.1.3: Growth Opportunities for the Global Cutaneous Bcell Lymphoma Treatment Market by Region
• 6.2: Emerging Trends in the Global Cutaneous Bcell Lymphoma Treatment Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Cutaneous Bcell Lymphoma Treatment Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cutaneous Bcell Lymphoma Treatment Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Kite Pharma
• 7.2: Genentech
• 7.3: Novartis
• 7.4: Epizyme
• 7.5: NanoString Technologies
• 7.6: Amgen
• 7.7: Johnson & Johnson Services